Connect with us

Politics

Dems Pick Anti-Marijuana Kennedy For Trump State Of The Union Response

Published

on

On Tuesday night, Congressman Joe Kennedy III of Massachusetts will deliver the official Democratic response to President Trump’s State of the Union address.

Some observers see the young Kennedy, 37, as a rising political star. But he is starkly out of step with his party — and a majority of U.S. voters — on a key issue now emerging at the forefront of mainstream American politics: Marijuana.

Kennedy’s Anti-Marijuana Voting Record

In 2015, Kennedy was one of just ten House Democrats to vote against a measure to protect medical cannabis patients and providers who are following state laws from being prosecuted by the federal government. He was one of just 24 Democrats to vote the same day against a broader measure blocking the Justice Department from interfering with all state marijuana laws, including those allowing recreational use.

Sixty-seven Republicans supported the medical cannabis measure that Kennedy opposed, and 45 GOP members supported the broader marijuana measure.

Going further than just refusing to block federal anti-marijuana enforcement in legal states, Kennedy voted three times against amendments to increase military veterans’ access to medical cannabis — just one of five Democrats to oppose the measure in 2016. Fifty-seven Republicans voted for it that year.

Kennedy even opposed a very limited proposal to protect children who use non-psychoactive cannabidiol extracts to treat severe seizure disorders from being targeted by the DEA. That amendment was supported by 118 Republicans.

The National Organization for the Reform of Marijuana Laws (NORML) gave Kennedy a D on its congressional scorecard.

Kennedy Is Out Of Step With Voters On Cannabis

Polling now shows that a growing majority of Americans supports legalizing marijuana, and medical cannabis enjoys supermajorty support, as does the notion of letting states end prohibition without federal interference.

Poll: Legal Marijuana Support At Record High In U.S.

This is especially true among Democrats. Gallup found last year that 72 percent of Democrats back broad legalization, and a Quinnipiac University survey this month showed that 95 percent of the party’s voters support medical cannabis.

The latter poll also showed that just 12 percent of Democrats want the federal government to interfere with state marijuana laws in line with Kennedy’s voting record.

On Marijuana, Voters Want Feds To Butt Out Of State Laws, Polls Find

Support for marijuana law reform is even stronger among the young people to whom Democrats are presumably trying to appeal by placing the youthful member of one of America’s most prominent political dynasties front and center with the State of the Union response.

The Quinnipiac survey found that 79 percent of American voters aged 18 to 34 back legalization. Only 17 percent in that demographic agree with Kennedy that the federal government should enforce cannabis prohibition in states that have opted to modernize their laws.

Kennedy Silent On Defending His State From Jeff Sessions

After U.S. Attorney General Jeff Sessions moved this month to rescind Obama-era guidance that has generally allowed states to implement their own marijuana laws without federal interference, congressional pushback was swift and strong, particularly among Democrats.

Lawmakers React To Sessions Anti-Marijuana Move

Kennedy was nowhere to be seen, however, even though voters in his home state of Massachusetts have strongly approved a string of marijuana-related ballot measures in recent years.

In 2008, 63 percent of Bay State voters approved a cannabis decriminalization measure. Four years later, 63 percent voted to legalize medical marijuana. And in 2016, 54 percent opted to go even further by legalizing marijuana for adult use — a measure that Kennedy campaigned against.

“At a time when Massachusetts is facing a crippling addiction crisis, increasing access to yet another controlled substance undermines the families, individuals, communities, law enforcement officials and health care workers on the front lines of this epidemic every single day,” he said a few weeks before the most recent Massachusetts ballot vote.

“I don’t think marijuana should be legalized,” Kennedy said in a separate interview. “If we’re going to say marijuana is a medicine, it needs to be treated like a medicine and regulated like a medicine. But when we look at full-on legalization, the potential danger that marijuana poses particularly to adolescents—I’m not convinced.”

He also co-hosted a fundraiser for the failed campaign to defeat the state legalization measure.

Now, because of the Trump administration’s cannabis reversal, Kennedy’s constituents are at increased risk of being arrested by the DEA and sent to federal prison, especially because the state’s U.S. attorney has delivered more concerning marijuana enforcement comments than prosecutors from other states have.

But instead of joining Democratic colleagues — and a significant number of Republicans — in pushing back on the federal marijuana attack, Kennedy’s voting record suggests he supports the move.

Kennedy’s Anti-Marijuana Family Ties Put Political Future At Risk

The congressman is related to former Rep. Patrick Kennedy of Rhode Island, who co-founded leading anti-legalization organization Smart Approaches to Marijuana, which is perhaps the simplest explanation for his tendency to vote against cannabis measures in contravention of the views of his constituents and party colleagues.

The younger Kennedy’s name has sometimes been floated as a potential 2020 presidential candidate, but with likely contenders like Cory Booker, Elizabeth Warren and Bernie Sanders staking out bold positions in favor of marijuana law reform that are much more in line with where Democratic primary voters are on the issue, it is likely that his opposition to all things cannabis would prove to be a political liability should he run.

Polling to date consistently suggests that President Trump’s anti-marijuana move is a political liability — particularly in light of his repeated campaign promises to the contrary about respecting state laws — if only Democrats would make a concerted effort to shine a spotlight on it.

For now, however, Democratic leaders appear to be leaving a ripe political issue on the table by putting an ardent cannabis opponent on a prominent pedestal for the State of the Union response.

Photo courtesy of Martin Grondin.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Tom Angell is the editor of Marijuana Moment. A 15-year veteran in the cannabis law reform movement, he covers the policy and politics of marijuana. Separately, he founded the nonprofit Marijuana Majority. Previously he reported for Marijuana.com and MassRoots, and handled media relations and campaigns for Law Enforcement Against Prohibition and Students for Sensible Drug Policy. (Organization citations are for identification only and do not constitute an endorsement or partnership.)

Politics

Feds Award $3 Million In Grants To Study Marijuana Ingredients As Alternatives To Opioids

Published

on

The federal government has awarded $3 million in grants for research into the therapeutic benefits of ingredients in marijuana other than THC, emphasizing their potential as alternatives to prescription opioids.

In a notice published on Thursday, the National Institutes of Health (NIH) explained why the studies were necessary and listed grant recipients and the subjects they will investigate. That includes research into the use of CBD for arthritis pain, which will be led by New York University School of Medicine.

“The treatment of chronic pain has relied heavily on opioids, despite their potential for addiction and overdose and the fact that they often don’t work well when used on a long-term basis,” Helene Langevin, director of the National Center for Complementary and Integrative Health (NCCIH), said in a press release. “There’s an urgent need for more effective and safer options.”

A total of nine grants were issued, with NIH stating that the funds will help identify alternative treatment options for pain and provide information about the impact of consuming cannabis compounds such as CBD and other lesser-known cannabinoids as well as terpenes found in the plant.

“The cannabis plant contains more than 110 cannabinoids and 120 terpenes, but the only compound that’s been studied extensively is THC,” the press release said.

But while THC is known to treat certain forms of pain, NIH is concerned that its intoxicating effects limit its medical applicability.

“THC may help relieve pain, but its value as an analgesic is limited by its psychoactive effects and abuse potential,” David Shurtleff, deputy director of NCCIH, said. “These new projects will investigate substances from cannabis that don’t have THC’s disadvantages, looking at their basic biological activity and their potential mechanisms of action as pain relievers.”

NIH first announced that it would be issuing grants for studies into minor cannabinoids and terpenes last year.

Federal health agencies aren’t the only institutions interested in learning about marijuana compounds other than THC. On Wednesday, a Senate committee issued a spending report that called for research into CBD and CBG while also criticizing the federal drug scheduling system for inhibiting such research.

Read descriptions of the federal cannabinoid and terpene research grant awards below:

Mechanism and Optimization of CBD-Mediated Analgesic Effects; Boston Children’s Hospital, Boston,; Zhigang He, Ph.D., B.M., and Juan Hong Wang, Ph.D. This project will investigate how the pain-relieving effects of cannabidiol (CBD) and other minor cannabinoids may be modulated by the activity of potassium-chloride cotransporter 2 (KCC2), a chloride extruder expressed in most neurons. (Grant 1R01AT010779)

Neuroimmune Mechanisms of Minor Cannabinoids in Inflammatory and Neuropathic Pain; University of California, San Francisco; Judith Hellman, M.D., and Mark A. Schumacher, M.D., Ph.D. This project will explore the effects of minor cannabinoids on inflammatory and neuropathic pain in vitro and in vivo, focusing on the interactions of the cannabinoids with the peripheral receptor called TRPV1 and a cannabinoid receptor, CB1R. (Grant 1R01AT010757)

Minor Cannabinoids and Terpenes: Preclinical Evaluation as Analgesics; Research Triangle Institute, Research Triangle Park, North Carolina; Jenny L. Wiley, Ph.D. This project will evaluate purified biosynthesized minor cannabinoids and selected terpenes alone and in planned combinations to determine their potential efficacy as pain relievers against acute thermal, inflammatory, neuropathic, and visceral pain. (Grant 1R01AT010773)

Identifying the Mechanisms of Action for CBD on Chronic Arthritis Pain; New York University School of Medicine, New York City; Yu-Shin Ding, Ph.D. This project will use neuroimaging studies and behavioral assessments to investigate the mechanisms of action of CBD in the modulation of chronic pain associated with osteoarthritis in a mouse model. (Grant 1R21AT010771)

Synthetic Biology for the Chemogenetic Manipulation of Pain Pathways; University of Texas, Austin; Andrew Ellington, Ph.D. This project will use a novel method to evolve individual variants of cannabinoid receptor type 2 (CB2) that interact with high affinity with minor cannabinoids and evaluate the new variants in a mouse model of pain. (Grant 1R21AT010777)

Exploring the Mechanisms Underlying the Analgesic Effect of Cannabidiol Using Proton Magnetic Resonance Spectroscopy; University of Utah, Salt Lake City; Deborah A. Yurgelun-Todd, Ph.D. This project will use proton magnetic resonance spectroscopy (1H-MRS) to evaluate changes in brain chemistry in critical pain-processing regions after short-term administration of a cannabis extract enriched in CBD. (Grant 1R21AT010736)

Mechanistic Studies of Analgesic Effects of Terpene Enriched Extracts from Hops; Emory University, Atlanta; Cassandra L. Quave, Ph.D. This project will take a multidisciplinary approach to investigate the analgesic effects of terpenes from Humulus lupulus (hops), a plant that is closely related to cannabis and has a very similar terpene profile. (Grant 1R21AT010774)

Systematic Investigation of Rare Cannabinoids With Pain Receptors; University of Illinois at Urbana-Champaign; David Sarlah, Ph.D. This project involves synthesizing several classes of rare phytocannabinoids, systematically evaluating their anti-inflammatory potential, and examining the effects of the compounds with the strongest anti-inflammatory potential on the major receptors involved in pain sensation. (Grant 1R21AT010761)

Analgesic efficacy of single and combined minor cannabinoids and terpenes; Temple University, Philadelphia; Sara J. Ward, Ph.D. This project will use rodent models of pain to evaluate the effects of four biologically active components of cannabis that may act synergistically to protect against pain development and to assess the interactions of these four substances with morphine. (Grant 1R01AT010778)

Senate Report Slams Drug Scheduling System For Blocking Marijuana Research

 

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Beto O’Rourke Proposes Drug War Reparations Funded By Marijuana Taxes

Published

on

Marijuana would not only be legalized under a plan proposed on Thursday by Democratic presidential candidate Beto O’Rourke, but cannabis tax revenue would be used to directly repay formerly incarcerated people through a new “Drug War Justice Grant” program.

Unlike other contenders who have come around to supporting marijuana legalization in just the past couple of years, the former Texas congressman has long called for ending prohibition—and his new plan in many respects goes further than those rolled out by other campaigns.

Please visit Forbes to read the rest of this piece.

(Marijuana Moment’s editor provides some content to Forbes via a temporary exclusive publishing license arrangement.)

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Support Grows For Marijuana Legalization Bill In Colombia

Published

on

Colombia’s legislature will soon take up a bill to legalize and regulate the production and consumption of marijuana for adults.

The legislation, which is being filed by Sen. Gustavo Bolivar of the opposition Colombia Humana party, seeks to end prohibition as a means of curtailing crime and supporting a public health-focused approach to drug policy.

Bolivar, an author who has written several books centered on drug trafficking, has characterized the bill as being about “regularization, not legalization,” but it would provide for legal sales to adults with restrictions similar to those imposed for tobacco and alcohol. There would be penalties for selling to underage individuals and smoking wouldn’t be permitted in public spaces.

The senator pointed to Uruguay, Canada and states in the U.S. as regulatory models for legalization.

“It has been proven that crime levels are lowered and public health is improved,” he said, according to Colombia Reports.

Sen. Alberto Castilla Salazar of the leftist Polo Democrático party said that his coalition supports the reform measure.

“Colombia must overcome prohibitionism and break the ties of illegal groups with the control of cannabis, so that it is the State that regulates, defines the forms and understands consumption as a public health problem,” he said on Tuesday.

Sen. Julián Gallo Cubillos of the FARC party said his coalition supports the legislation and that it represents “a new way to fight the scourge of drug trafficking.”

The proposal has also garnered the support of former President Juan Manuel Santos, who has been an outspoken advocate for ending the war on drugs. His Liberal party could make or break the legislation depending on where members fall.

While left and center-left lawmakers seem largely united around legalizing marijuana, the issue will likely face resistance from President Ivan Duque, who last year signed a decree banning low-level possession of cannabis and cocaine despite court rulings that such activity is permissible.

As Colombia Reports noted, however, Duque’s far-right Democratic Center party is in the minority.

“We’ll have to see how many senators are left to former president Juan Manuel Santos and see how public opinion receives the idea that marijuana can be consumed in public spaces,” Sen. Paloma Valencia, a member of the president’s party, said.

If the country does opt to pursue a regulated cannabis program, it will join Mexico, where lawmakers are readying legislation to legalize marijuana for adult use following a Supreme Court ruling establishing that a ban on possession and cultivation for personal use is unconstitutional.

Former White House Drug Czar Offers Marijuana Legalization Advice To Mexico

Photo courtesy of Brian Shamblen.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Stay Up To The Moment

Marijuana News In Your Inbox


Support Marijuana Moment

Marijuana News In Your Inbox

Do NOT follow this link or you will be banned from the site!